At the completion of this educational activity, the learner will be able to:
1. Explain the rationale supporting routine genetic testing in the evaluation of patients with non-ischemic cardiomyopathies.
2. Discuss the importance of cascade genetic screening for early diagnosis of family members.
3. Review novel therapeutics for genetic cardiomyopathies.

In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.25 MOC contact hours in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.  Learners should claim only the credit commensurate with the extent of their participation in the activity.

 This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.